I have a research focus in adoptive T cell therapy using chimeric antigen receptors (CARs) and checkpoint inhibitors. My current interest is on the design of next generation of CARs and combination checkpoint immunotherapy in the setting of a tolerant/suppressive tumor microenvironment in solid malignancies.
Translating recent advancements in cellular cancer immunotherapy to metastatic solid tumors has been especially challenging, and this is highlighted by the lack clinical response outside of the CD19 ideal antigen as target. Current forms of therapy is likely insufficient to overcome the naturally tolerogenic microenvironment evolved to protect against autoimmunity. Using the liver as a model organ of immune tolerance, I intend to study the mechanism of tumor escape in the setting of checkpoint inhibition and adoptive T cell therapy.
My hope is to see cancer immunotherapeutics become its own mainstream anatomic-site agnostic cancer subspecialty.
Clinical Instructor, Memorial Sloan-Kettering Cancer Center, New York, NY. July 2012-July 2013
Clinical Instructor, University of California, San Francisco, CA. July 2013-July 2014
Medical School: Yale School of Medicine, New Haven, CT. September 2003-May 2009
Research Fellowship: Memorial Sloan-Kettering Cancer Center, New York, NY. 2006-2009.
Residency: Mount Sinai Medical Center, New York, NY. July 2009-June 2012